These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 21813788)

  • 1. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.
    Costanzi C; Matiello M; Lucchinetti CF; Weinshenker BG; Pittock SJ; Mandrekar J; Thapa P; McKeon A
    Neurology; 2011 Aug; 77(7):659-66. PubMed ID: 21813788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder.
    Chen H; Qiu W; Zhang Q; Wang J; Shi Z; Liu J; Lian Z; Feng H; Miao X; Zhou H
    Eur J Neurol; 2017 Jan; 24(1):219-226. PubMed ID: 27783452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
    JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
    Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
    Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
    Jacob A; Weinshenker BG; Violich I; McLinskey N; Krupp L; Fox RJ; Wingerchuk DM; Boggild M; Constantinescu CS; Miller A; De Angelis T; Matiello M; Cree BA
    Arch Neurol; 2008 Nov; 65(11):1443-8. PubMed ID: 18779415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica.
    Qiu W; Kermode AG; Li R; Dai Y; Wang Y; Wang J; Zhong X; Li C; Lu Z; Hu X
    J Clin Neurosci; 2015 Jul; 22(7):1178-82. PubMed ID: 26006157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the treatment of neuromyelitis optica.
    Torres J; Pruitt A; Balcer L; Galetta S; Markowitz C; Dahodwala N
    J Neurol Sci; 2015 Apr; 351(1-2):31-35. PubMed ID: 25727350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuromyelitis optica in France: a multicenter study of 125 patients.
    Collongues N; Marignier R; Zéphir H; Papeix C; Blanc F; Ritleng C; Tchikviladzé M; Outteryck O; Vukusic S; Fleury M; Fontaine B; Brassat D; Clanet M; Milh M; Pelletier J; Audoin B; Ruet A; Lebrun-Frenay C; Thouvenot E; Camu W; Debouverie M; Créange A; Moreau T; Labauge P; Castelnovo G; Edan G; Le Page E; Defer G; Barroso B; Heinzlef O; Gout O; Rodriguez D; Wiertlewski S; Laplaud D; Borgel F; Tourniaire P; Grimaud J; Brochet B; Vermersch P; Confavreux C; de Seze J
    Neurology; 2010 Mar; 74(9):736-42. PubMed ID: 20194912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?
    Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
    Mult Scler; 2012 Oct; 18(10):1480-3. PubMed ID: 22354738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
    Kitley J; Elsone L; George J; Waters P; Woodhall M; Vincent A; Jacob A; Leite MI; Palace J
    J Neurol Neurosurg Psychiatry; 2013 Aug; 84(8):918-21. PubMed ID: 23467418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
    Viswanathan S; Wong AH; Quek AM; Yuki N
    J Neuroimmunol; 2015 May; 282():92-6. PubMed ID: 25903734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China.
    Chen H; Zhang Y; Shi Z; Feng H; Yao S; Xie J; Zhou H
    Clin Neuropharmacol; 2016; 39(2):81-7. PubMed ID: 26818042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
    Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
    J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuromyelitis optica treatment: analysis of 36 patients.
    Bichuetti DB; Lobato de Oliveira EM; Oliveira DM; Amorin de Souza N; Gabbai AA
    Arch Neurol; 2010 Sep; 67(9):1131-6. PubMed ID: 20837859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study.
    Zhang M; Zhang C; Bai P; Xue H; Wang G
    Acta Neurol Belg; 2017 Sep; 117(3):695-702. PubMed ID: 28608315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of neuromyelitis optica with a pediatric onset.
    Collongues N; Marignier R; Zéphir H; Papeix C; Fontaine B; Blanc F; Rodriguez D; Fleury M; Vukusic S; Pelletier J; Audoin B; Thouvenot E; Camu W; Barroso B; Ruet A; Brochet B; Vermersch P; Confavreux C; de Seze J
    Neurology; 2010 Sep; 75(12):1084-8. PubMed ID: 20855851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
    Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F
    Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.
    Elsone L; Kitley J; Luppe S; Lythgoe D; Mutch K; Jacob S; Brown R; Moss K; McNeillis B; Goh YY; Leite MI; Robertson N; Palace J; Jacob A
    Mult Scler; 2014 Oct; 20(11):1533-40. PubMed ID: 24647557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMO-IgG predicts the outcome of recurrent optic neuritis.
    Matiello M; Lennon VA; Jacob A; Pittock SJ; Lucchinetti CF; Wingerchuk DM; Weinshenker BG
    Neurology; 2008 Jun; 70(23):2197-200. PubMed ID: 18434643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.